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activation of the complement cascade and accumulation of membrane
attack complexes (MAC) around drusen and in the choroid (Mullins
et al., 2014).
Therefore, reducing the lipid burden in AMDwithout causing RPE at-
rophy or stimulating CNV is a desirable outcome and merits investiga-
tion. Previous interventions such as laser to reduce drusen have notLipids
AMD
Retina
Eye
Macular degeneration
Cholesterol
Inﬂammation
macrophageAge-related macular degeneration (AMD) is the leading cause of
blindness among people over 50 years of age in the industrialized
world (van Leeuwen et al., 2003). A cardinal clinical feature of the dis-
ease is extracellular deposition of lipid-rich deposits underneath the
retinal pigmented epithelium (RPE) called drusen, which contain high
amounts of esteriﬁed and unesteriﬁed cholesterol (Curcio et al., 2005).
In AMD, lipid accumulation can also be observed as sub-retinal
drusenoid deposits or as thickening of the Bruch's membrane, an
elastin-rich layer that separates the RPE from the choriocapillaris. Al-
though drusen themselves do not always affect vision, they typically
precede advanced AMD, which is associated with vision loss. Advanced
AMD occurs in two forms that can co-exist: a) geographic atrophy (GA)
associated with loss of RPE cells and b) choroidal neovascularization
(CNV) characterized by proliferative, anomalous growth of blood ves-
sels underneath the retina that leads to hemorrhage and ﬁbrosis (Fig.
1). Both GA and CNV ultimately cause vision loss due to photoreceptor
cell death.
Recent studies demonstrate that lipid deposits in AMD serve as a
nidus for disease progression (Sene and Apte, 2014; Sene et al., 2013,
2015). There are multiple mechanisms by which drusen and other ex-
tracellular lipids get deposited underneath the retina and accelerate dis-
ease pathogenesis: i) age-associated impairment of cholesterol
homeostasis and reverse cholesterol transport (RCT) by macrophages
and RPE, ii) lipid mediated RPE dysfunction and iii) activation of them.2016.01.033.
. This is an open access article underbeen successful (Virgili et al., 2015). In this issue of EBioMedicine, Vavvas
et al. report anatomic and visual outcomes of a prospectively designed,
non-randomized lipid lowering strategy in patients with AMD (Vavvas
et al., 2016). They demonstrate a quantitative reduction in drusen vol-
ume in 10 of 23 patients placed on high dose, oral atorvastatin without
signiﬁcant change in visual acuity. Although baseline cholesterol levels
of participants were reported, lipid proﬁling including lipid class and li-
poprotein particle size information was not reported. These measure-
ments may have provided key insights into why there was no
correlation between drusen reduction and serum lipid response to ator-
vastatin in this study. Carefully collected baseline lipid metrics will be
essential in future studies.
This study is very relevant since prior epidemiological studies have
reported conﬂicting results regarding the efﬁcacy of statins in AMDpro-
gression (Maguire et al., 2009). The report by Vavvas et al. illustrates the
complexity of lipid modulation as a therapeutic strategy (Vavvas et al.,
2016). There are several unanswered questions: a) Is the natural history
of disease always associated with an increase in drusen volume? A
matched control group would be necessary to make deﬁnitive conclu-
sions; b) Does an increase in drusen volume correlate with increased
risk for developing GA or CNV?; c) Is there an association between a re-
duction in macular drusen and RPE atrophy as has been previously re-
ported?; d) What is the optimal time and dose of treatment to assess
therapeutic response and side effects so that the risk to beneﬁt ratio
can be reduced? These questions mandate large, randomized prospec-
tive studies. As such, we should exercise caution in interpreting the re-
sults of this small, prospective cohort.
We may be on the cusp of potential breakthroughs in lipid-targeted
treatment of AMD. Genome wide association studies (GWAS) of AMD
patients have demonstrated polymorphisms inmultiple genes involved
in cholesterol homeostasis (Neale et al., 2010). Some examples are ATP-
binding cassette transporter member 1 (ABCA1), which plays a key role
in RCT, and genes such as hepatic lipase (LIPC) and cholesteryl ester
transfer protein (CETP), which are involved in regulating HDL. Of inter-
est, polymorphisms identiﬁed through GWAS suggest that lipid regula-
tion and deposition in the eye is complex and may require targeted
strategies beyond modulation of a single lipid class. Such strategies
may include microRNA (miR) silencing approaches that target speciﬁcthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Natural history of age-relatedmacular degeneration (AMD) andpotential role of lipid targeted therapies. Early AMD is characterized by lipid richdrusen, sub-retinal drusenoid
deposits, and thickening of Bruch's membrane (BM) alongwith abnormalities in the retinal pigmented epithelium (RPE). Macrophage-mediated inﬂammation, complement activation as
manifested by the deposition of membrane attack complexes (MAC), and RPE dysfunction lead to advanced disease characterized by choroidal neovascularization (CNV) and geographic
atrophy (GA). Potential therapeutic approaches to prevent complications of AMD are highlighted. PR = photoreceptor neurons.
27R.S. Apte / EBioMedicine 5 (2016) 26–27miRs, such as miR33, to regulate cholesterol synthesis and RCT; Liver X
receptor (LXR) agonists to enhance RCT; and CETP modulators to alter
serum HDL and particle size (Sene and Apte, 2014). These novel treat-
ment approaches may synergize with other existing strategies such as
statins to reduce cholesterol synthesis. Given the complexity of choles-
terol homeostasis, each of these pathways will need careful investiga-
tion for efﬁcacy and safety in animal models and randomized clinical
trials that are adequately powered to probe these associations. Individ-
ualized therapymay be required depending on the pathways affected in
each individual. It is biologically plausible that different pathways lead
to drusen formation even though the ultimate phenotype is similar. If
successful, this approach will usher in a new era in AMD therapy
where disease can be targeted at an earlier stage.
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